BG
CDTX

Bollard Group’s Cidara Therapeutics CDTX Stock Holding History

Bollard Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-387
Closed -$6K – 304
2022
Q1 		$6K Hold
387
– – ﹤0.01% 413
2021
Q4 		$10K Hold
387
– – ﹤0.01% 411
2021
Q3 		$17K Hold
387
– – ﹤0.01% 395
2021
Q2 		$16K Hold
387
– – ﹤0.01% 398
2021
Q1 		$21K Hold
387
– – ﹤0.01% 392
2020
Q4 		$15K Hold
387
– – ﹤0.01% 398
2020
Q3 		$22K Hold
387
– – ﹤0.01% 380
2020
Q2 		$29K Buy
+387
New +$25.1K ﹤0.01% 390

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bollard Group's CDTX Position: Q2 2022 in Review

Bollard Group sold out of Cidara Therapeutics (CDTX) in Q2 2022, closing a stake of 387 shares — an estimated $6K sold.

Bollard Group first reported a position in CDTX in Q2 2020 and held it in 8 quarters. The position peaked at $29K in Q2 2020. 46 funds tracked by Wall St. Rank hold CDTX as of Q2 2022.

  • Bollard Group reported no remaining Cidara Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bollard Group sold 387 Cidara Therapeutics shares in Q2 2022, an estimated $6K.
  • Bollard Group first reported a position in Cidara Therapeutics in Q2 2020 and held it in 8 quarters.
  • Bollard Group's Cidara Therapeutics position peaked at $29K in Q2 2020.
  • 46 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.